Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $948K | $394K | $444K | $2.02M | $1.64M | $2.37M | $1.88M | $0.00 | $225K | $400K |
| Revenue growth | — | -58.4% | 12.7% | 354.5% | -18.8% | 44.7% | -20.5% | -100.0% | — | 77.8% |
| Gross profit | — | — | — | — | $935K | $909K | $2.17M | — | — | — |
| Gross margin | — | — | — | — | 57.1% | 38.3% | 115.0% | — | — | — |
| Operating income | -$9.89M | -$14.3M | -$14.2M | -$15.8M | -$14.0M | -$31.1M | -$29.7M | -$29.3M | -$16.6M | -$18.6M |
| Operating margin | -1043.6% | -3622.8% | -3204.3% | -782.4% | -854.9% | -1312.1% | -1576.3% | — | -7392.9% | -4650.5% |
| Net income | -$9.76M | -$14.5M | -$16.1M | -$17.6M | -$16.4M | -$23.2M | -$50.3M | -$65.0M | -$24.9M | -$18.4M |
| Net margin | -1030.0% | -3688.3% | -3627.3% | -871.8% | -1003.6% | -978.8% | -2670.0% | — | -11069.8% | -4594.3% |
| EPS (diluted) | -$0.12 | -$1.64 | -$1.54 | -$0.94 | -$0.61 | -$3.00 | -$5.78 | -$106.19 | -$6.50 | -$1.75 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.07M | -$13.2M | -$13.5M | -$14.0M | -$13.3M | -$30.1M | -$37.5M | -$30.4M | -$18.6M | -$15.3M |
| Capital expenditures | $68.0K | $1.32M | $934K | $920K | $1.08M | $4.92M | $7.33M | $5.74M | $210K | $16.0K |
| Free cash flow | -$8.14M | -$14.5M | -$14.4M | -$14.9M | -$14.4M | -$35.0M | -$44.8M | -$36.2M | -$18.8M | -$15.3M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15.9M | $15.9M | $4.42M | $4.42M | $55.1M | $77.4M | $22.7M | $4.30M | $14.2M | $8.58M |
| Total assets | $51.6M | $36.0M | $43.1M | $30.6M | $94.2M | $147M | $99.4M | $41.2M | $28.7M | $23.2M |
| Total liabilities | $27.6M | $27.1M | $26.9M | $28.1M | $37.6M | $38.4M | $35.9M | $25.8M | $7.41M | $8.30M |
| Shareholders' equity | $9.94M | $8.91M | $16.2M | $2.46M | $56.6M | $109M | $63.5M | $15.4M | $21.3M | $14.9M |
| Retained earnings | -$57.6M | -$72.1M | -$88.2M | -$106M | -$150M | -$174M | -$224M | -$289M | -$314M | -$332M |
| Shares (wtd avg diluted) | 89.1M | 8.91M | 16.0M | 20.2M | 140M | 7.83M | 8.72M | 612K | 3.83M | 10.5M |
Every figure is extracted from iBio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.